Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

News Briefs

Diane Cope
CJON 2002, 6(3), 124-125 DOI: 10.1188/02.CJON.124-125

On February 1, the U.S. Food and Drug Administration (FDA) approved Gleevecâ„¢ (imantinib mesylate, Novartis Pharmaceuticals, Basel, Switzerland) for the treatment of patients with metastatic or unresectable malignant gastrointestinal stromal tumors (GIST).

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or